Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00417170 · ClinicalTrials.gov registry record · Phase 2
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00417170 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT00417170, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the effects of Aliskiren on insulin resistance (IR) and endothelial dysfunction (ED) in patients with high blood pressure and metabolic syndrome. The efficacy of Aliskiren was compared to Amlodipine.
Interventions
- DRUG Amlodipine
- DRUG Aliskiren
- DRUG Placebo Aliskiren
- DRUG Placebo Amlodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00417170
The ClinicalTrials.gov registry entry for NCT00417170 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Amlodipine is the first listed.
NCT00417170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00417170 about?
NCT00417170 is a clinical study titled "Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome". The purpose of this study was to determine the effects of Aliskiren on insulin resistance (IR) and endothelial dysfunction (ED) in patients with high blood pressure and metabolic syndrome. The efficacy of Aliskiren was compared to Amlodipine.
What is the current status of trial NCT00417170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2007-10. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00417170?
The interventions under investigation include: Amlodipine (DRUG), Aliskiren (DRUG), Placebo Aliskiren (DRUG), Placebo Amlodipine (DRUG).
Who is sponsoring clinical trial NCT00417170?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.